This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Analysts Estimate Veru Inc. (VERU) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Veru Inc. (VERU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Veru Inc. (VERU) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Veru Inc. (VERU) delivered earnings and revenue surprises of 50.00% and 26.32%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Veru Inc. (VERU) Q3 Earnings Expected to Decline
by Zacks Equity Research
Veru Inc. (VERU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Veru Inc. (VERU) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Veru Inc. (VERU) delivered earnings and revenue surprises of -33.33% and -7.12%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Why Veru (VERU) Might Surprise This Earnings Season
by Zacks Equity Research
Veru (VERU) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Veru Inc. (VERU) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Veru Inc. (VERU) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Top-Line Growth Buoy Motorola's (MSI) Q1 Earnings?
by Zacks Equity Research
With a healthy demand across land mobile radio products and other devices, Motorola Solutions (MSI) is likely to have generated higher consolidated revenues in Q1 despite the coronavirus-led turmoil.
Are Options Traders Betting on a Big Move in Veru (VERU) Stock?
by Zacks Equity Research
Investors need to pay close attention to Veru (VERU) stock based on the movements in the options market lately.
Veru (VERU) Reports Q1 Loss, Tops Revenue Estimates (Revised)
by Zacks Equity Research
Veru (VERU) delivered earnings and revenue surprises of 50.00% and 37.56%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Female Health Company The (VERU) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Female Health Company The (VERU) delivered earnings and revenue surprises of 50.00% and 37.56%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Will Female Health Company The (VERU) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Female Health Company The (VERU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Implied Volatility Surging for Veru (VERU) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Veru (VERU) stock based on the movements in the options market lately.
Do Options Traders Know Something About Veru (VERU) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Veru (VERU) stock based on the movements in the options market lately.
Do Options Traders Know Something About Veru (VERU) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Veru (VERU) stock based on the movements in the options market lately.
Veru (VERU) Soars: Stock Adds 6.9% in Session
by Zacks Equity Research
Veru (VERU) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Top Ranked Momentum Stocks to Buy for January 29th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, January 29th
Will Veru Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Veru.
Will Veru Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Veru.
Options Traders Expect Huge Moves in Veru (VERU) Stock
by Zacks Equity Research
Investors need to pay close attention to Veru (VERU) stock based on the movements in the options market lately.
Veru (VERU) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
by Zacks Equity Research
Veru (VERU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Veru (VERU) Q1 Earnings Expected to Decline
by Zacks Equity Research
Veru (VERU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Stryker (SYK) to Gain From Solid Portfolio and Acquisitions
by Zacks Equity Research
Stryker's (SYK) diverse portfolio and accretive acquisitions is instrumental in aiding the company's top-line growth.
4 Momentum Stocks That May Survive the Health Policy Mess
by Zacks Equity Research
In view of the current political scenario and banking on favorable metrics, these four MedTech stocks stand out as the most suitable momentum picks.
Stryker (SYK) to Gain From Solid Portfolio and Acquisitions
by Zacks Equity Research
Stryker Corporation (SYK) has successfully expanded its product portfolio over time, which aids the company to cater to evolving demands of customers.